
GoodRx Holdings, Inc.: updates and filings
Price
$3.02
November 19, 2026Market cap $1.1B
What Ploutos Investor adds for GoodRx
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from 2018
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Aug 5, 2026next Nov 5, 2026
An estimate from when it has reported before, which has been regular. The company announces the date itself.
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 10, 2026Notice that the quarterly report will be filed lateFormNT 10-Q
- Nov 2, 2026Previous financial statements not to be relied onForm8-K
- Aug 26, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Aug 5, 2026Officer or director changeForm8-K
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operationsForm8-K
- Jun 18, 2026Shareholder voteForm8-K
- May 6, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Results of operationsForm8-K
- Apr 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 29, 2026Additional annual meeting materialFormDEFA14A
- Apr 29, 2026Annual meeting proxy statementFormDEF 14A
- Apr 24, 2026Officer or director changeForm8-K
- Apr 3, 2026Officer or director changeForm8-K
- Mar 27, 2026Officer or director changeForm8-K
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 18, 2026Change of auditorForm8-K
- Mar 6, 2026Officer or director changeForm8-K
- Feb 27, 2026Officer or director changeForm8-K
- Feb 26, 2026Shares registered for employeesFormS-8
- Feb 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 25, 2026Results of operationsForm8-K
- Dec 12, 2025Officer or director changeForm8-K
- Nov 4, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 10, 2026 | NT 10-Q | Notice that the quarterly report will be filed late | Document |
| Nov 2, 2026 | 8-K | Previous financial statements not to be relied on | Document |
| Aug 26, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Aug 5, 2026 | 8-K | Officer or director change | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations | Document |
| Jun 18, 2026 | 8-K | Shareholder vote | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | 8-K | Results of operations | Document |
| Apr 29, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 29, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 29, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 24, 2026 | 8-K | Officer or director change | Document |
| Apr 3, 2026 | 8-K | Officer or director change | Document |
| Mar 27, 2026 | 8-K | Officer or director change | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 18, 2026 | 8-K | Change of auditor | Document |
| Mar 6, 2026 | 8-K | Officer or director change | Document |
| Feb 27, 2026 | 8-K | Officer or director change | Document |
| Feb 26, 2026 | S-8 | Shares registered for employees | Document |
| Feb 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 25, 2026 | 8-K | Results of operations | Document |
| Dec 12, 2025 | 8-K | Officer or director change | Document |
| Nov 4, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 16, 2020.
The full analysis
What do GoodRx's filings show?
The filings are where every one of GoodRx's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.